The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

FATE FINANCIAL STATEMENTS

Fate Therapeutics Inc — balance sheet, income statement and cash flow trends

FATEFate Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-200 M0202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue6.5 M $Gross Profit-22.3 M $ · -343%Operating Income-133.6 M $ · -2058%Pre-tax Income-126 M $ · -1941%Net Income to Owners-126 M $ · -1941%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue6.5 M $-23.4%
Gross Profit-22.3 M $—
Operating Income-133.6 M $—
EBITDA-117.2 M $—
Net Income to Owners-126 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0500 M1 B202120222023202420252026

Capital Structure

Q2 2026
Total Assets260.1 M
  • Equity153.4 M $59%
  • Current Liabilities32.6 M $13%
  • Long-term Liabilities74.1 M $28%

Key Figures

YoY change
Total Assets260.1 M $-30.0%
Total Liabilities106.7 M $-3.3%
Total Equity153.4 M $-41.3%
Cash & ST Investments153.8 M $-31.0%
Total Debt75.7 M $-7.0%
Net Debt43.2 M $+7.9%

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-300 M-200 M-100 M0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-100 M-50 M0-101.9 M $Operating87 M $Investing5.9 M $Financing-9 M $Net Change

Key Figures

YoY change
Operating Cash Flow-101.9 M $—
Capital Expenditures3.7 M $+17.9%
Free Cash Flow-105.7 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on FATE

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 2, 26. This content is for informational purposes only and is not investment advice.